Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2

Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2

This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people (117 with prior COVID-19 and 229 without prior COVID...

Full description

Bibliographic Details
Main Authors: Jorge Hernández-Bello, José Javier Morales-Núñez, Andrea Carolina Machado-Sulbarán, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Paulina Balcázar-Félix, Jesús Alberto Gutiérrez-Brito, José Alvaro Lomelí-Nieto, José Francisco Muñoz-Valle
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Vaccines
Subjects:
COVID-19
SARS-CoV-2
AD5-nCOV
neutralizing antibodies
vaccine
reactogenicity
Online Access:https://www.mdpi.com/2076-393X/9/9/1047

Internet

https://www.mdpi.com/2076-393X/9/9/1047

Similar Items